Latest news with #obstructive
Medscape
14-05-2025
- Health
- Medscape
Study Links Pre-COVID Lung Health to Severe COVID-19 Risk
In a large US cohort study, pre-pandemic severe obstructive lung function, as measured by spirometry, was linked to more than a twofold increased risk for severe COVID-19. METHODOLOGY: Researchers analyzed the association of pre-pandemic measures of lung function and structure with the risk for severe COVID-19 using data from 11 prospective US population-based cohorts. Overall, 29,323 participants (mean age, 67.1 years) with valid pre-pandemic lung function and incident COVID-19 data were followed up for a median of 17.3 months from March 1, 2020. Pre-pandemic spirometry data were used to classify lung function: Normal physiology (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] ratio ≥ 0.70 and FVC ≥ 80% of the predicted value). Obstructive physiology (FEV1/FVC ratio < 0.70) and severe obstruction (FEV1 < 50% of the predicted value). Restrictive physiology (FEV1/FVC ratio ≥ 0.70 and FVC < 80% of the predicted value). Structural abnormalities, including emphysema and interstitial lung abnormalities such as lung distortion, honeycombing, traction bronchiectasis, nonemphysematous cysts, and ground-glass or reticular opacities, were assessed on CT scans. The primary outcome was severe COVID-19 (COVID-19 leading to hospitalization or death), and the secondary outcome was nonsevere COVID-19 (SARS-CoV-2 infection not requiring hospitalization). TAKEAWAY: Severe obstructive physiology and restrictive physiology were associated with an increased risk for severe COVID-19 compared with normal spirometry, with adjusted hazard ratios (aHRs) of 2.11 (95% CI, 1.36-3.27) and 1.40 (95% CI, 1.12-1.76), respectively. The risk for severe COVID-19 was 1.64-fold higher risk among those in the highest quartile than among those in the lowest quartile of percent emphysema (95% CI, 1.03-2.61). Higher pre-pandemic FEV1 and FVC levels and being in the highest quartile of percent high attenuation areas (indicative of interstitial lung disease) were associated with an increased risk for nonsevere COVID-19. COVID-19 vaccination was associated with a reduced risk for severe disease across all lung function and structure categories (aHR, 0.19-0.50; P for interaction > .30). IN PRACTICE: 'These findings support enhanced COVID-19 risk mitigation, including COVID-19 vaccination, for individuals with impaired lung health,' the authors wrote. SOURCE: This study was led by Pallavi P. Balte, MBBS, PhD, Division of General Medicine, Columbia University Irving Medical Center, New York City. It was published online on April 16, 2025, in American Journal of Respiratory and Critical Care Medicine . LIMITATIONS: This study primarily collected data during the pre-Omicron period, limiting the generalizability of the findings to current variants. Additionally, some cohort studies recruited participants who were healthier than average, while others oversampled individuals with disease, affecting population representativeness. DISCLOSURES: This study was supported by a grant from the National Heart, Lung, and Blood Institute; reported receiving co-funding from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging; and reported receiving additional funding from the American Lung Association. Six authors reported having financial ties with various pharmaceutical companies and research organizations.
Yahoo
03-04-2025
- Business
- Yahoo
US Plasma Fractionation Market worth US$13.80 billion by 2028 with 6.4% CAGR
DELRAY BEACH, Fla., April 3, 2025 /PRNewswire/ -- The global US Plasma Fractionation Market is projected to reach US$13.80 billion by 2028 from US$10.13 billion in 2023, at a CAGR of 6.4% during the forecast period. The increasing use of immunoglobulins in a variety of therapeutic fields, as well as the market's players' strategic expansion of plasma collection centers and inventories, along with the rising incidence of respiratory diseases like alpha-1-antitrypsin deficiency (AATD) and Chronic obstructive pulmonary disease (COPD), are the main factors driving the market's expansion. Download PDF Brochure: Browse in-depth TOC on "US Plasma Fractionation Market" 150 - Tables47 - Figures140- Pages By Based on Product, the US plasma fractionation market is segmented into protease inhibitors, coagulation factor concentrates, immunoglobulins, albumins, and other products. Immunoglobulins accounted for the largest share of the US plasma fractionation market in 2022. The dominance of this segment is mainly attributed to the rise in the cases of neurological and immunological diseases, the increase in off-label utilization of immunoglobulins, especially IVIg, and the increased usage of these immunoglobulins in the treatment of a variety of diseases and conditions that are linked to humoral immune deficiency or immune system dysfunction, including immune thrombocytopenic purpura, Kawasaki syndrome, Guillain-Barré syndrome, and graft-versus-host diseases after bone marrow transplantation. Additionally, the immunoglobins segment is anticipated to register the highest growth throughout the forecast period, based on volume. Owing to the broader range of medical indications, including autoimmune diseases, primary immunodeficiency disorders, neurological disorders, etc., and larger patient population served, IVIg typically contributes the most significant volume within the immunoglobulins segment of the US plasma fractionation market. By Based on application, the US plasma fractionation market is segmented into pulmonology, hemato-oncology neurology, immunology, hematology, critical care, rheumatology, and other applications. In 2022, the pulmonology segment is expected to register the highest CAGR during the forecast period. The increasing demand for immunoglobulins to prevent and treat upper and lower respiratory tract infections due to their efficiency is a major factor driving growth in this market segment. Additionally, the use of protease inhibitors such as alpha-1-antitrypsin has also increased substantially over the past few years. Request Sample Pages : Key players in the US plasma fractionation market include ADMA Biologics (US), and Emergent BioSolutions (US). Study Coverage The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the US plasma fractionation market. A detailed analysis of the key industry players has been done to provide insights into their business overviews, products and services, key strategies, acquisitions, new product/service approvals, expansions, agreements, and recent developments associated with the US plasma fractionation market. For more information, Inquire Now! Related Reports: Hematology Analyzers and Reagents Market Blood Culture Tests Market Apheresis Market Cold Plasma Market Cold Chain Products Market About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
